BACKGROUND AND AIM: We aimed to identify ischemia-modified albumin (IMA) levels 
in inflammatory bowel disease (IBD) and IBD subgroups, and to examine its 
relation with disease activity index.
METHODS: Sixty-eight patients with IBD (35 ulcerative colitis [UC] and 33 crohn 
disease [CD]) and 65 healthy volunteers were included in the study. Rachmilewitz 
scoring system (endoscopic activity index [EAI]) was used to determine UC 
activity, and as for CD activity, CD activity index (CDAI) scoring was used. IMA 
measurement was performed with ELISA kit.
RESULTS: Ischemia-modified albumin levels in IBD, UC, and CD groups were 
comparably higher than the control group (37.7 ng/mL vs 42.4 ng/mL vs 36.4 ng/mL 
vs 21.8 ng/mL, respectively; P < 0.05). In IBD group, a positive correlation was 
identified between IMA level and CRP (r = 0.325, P = 0.011), EAI(r = 0.302, 
P = 0.020), and CDAI (r = 0.311, P = 0.013). In stepwise regression model; it 
was identified that IMA(OR = 1.496; P = 0.016) and CRP(OR = 3.457; P = 0.015) 
are predictors of IBD in comparison with the control group. In linear regression 
model, it was identified that risk factors such as log(IMA) and log(CRP) were 
independent predictors of log(CDAI) and log(EAI) levels.
CONCLUSION: This is the first study showing that IMA levels in IBD were 
determined higher in comparison with the control group. Moreover, IMA being a 
predictor for IBD and being positively correlated with disease activity indexes 
were determined for the first time in the study. In accordance with these 
results, it is possible to say that IMA in IBD might be related with the 
pathogenesis of disease and correlated with the severity of the disease.